查看購物車
  • Simplified Chinese
  • English
2031年亞太細胞和基因治療市場預測—區域分析—按類型、服務、規模、服務提供者和最終用戶
市場調查報告書
商品編碼
1764841

2031年亞太細胞和基因治療市場預測—區域分析—按類型、服務、規模、服務提供者和最終用戶

Asia Pacific Cell and Gene Therapy Market Forecast to 2031 - Regional Analysis - by Type, Services, Scale, Service Providers, and End User
出版日期: | 出版商: The Insight Partners | 英文 161 Pages | 訂單完成後即時交付

價格

2023 年亞太細胞和基因治療市值為 10.2437 億美元，預計到 2031 年將達到 80.1275 億美元；預計 2023 年至 2031 年的複合年成長率為 29.3%。

公司策略措施推動亞太細胞和基因治療市場

許多參與細胞和基因治療產品生產的公司專注於合作、擴張、協議、夥伴關係、新產品發布和其他策略發展。這些策略舉措有助於他們提高銷售額、擴大地理覆蓋範圍並增強服務龐大客戶群的能力。細胞和基因治療市場的一些重要發展包括：2023年9月，安捷倫科技公司與新加坡先進細胞治療與研究中心（ACTRIS）簽署了一份合作備忘錄（MOU）。該協議旨在未來三年推動細胞和基因治療領域的進步。 2023年3月，Cellevolve Bio與西雅圖兒童治療公司合作，開發並商業化用於治療兒童癌症的新型多重嵌合抗原受體（CAR）藥物。透過此次合作，兩家公司將專注於BrainChild研究計畫——一套由五種多重CAR組成的方案——用於治療兒童中樞神經系統（CNS）惡性腫瘤。他們計劃利用西雅圖兒童治療工廠的設施進行新型CAR的早期臨床GMP研究。 2023年3月，Twist Bioscience Corporation與Kriya Therapeutics, Inc.達成一項抗體發現協議，旨在開發利用腺相關病毒(AAV)基因療法遞送的抗體，用於腫瘤治療應用。此外，兩家公司還計劃將Twist的抗體庫與Kriya專有的載體工程平台結合，以發現針對特定標靶的新型抗體，並利用Kriya的基因治療技術進行遞送。 2023年1月，富士軟片株式會社同意收購Atara Biotherapeutics, Inc.旗下的一家細胞療法生產廠。該工廠將進行擴建，以靈活地生產臨床和商業細胞療法，例如同種異體T細胞和CAR-T免疫療法。透過合作和夥伴關係開展新業務以保持市場競爭力，有助於加速開發新的細胞和基因療法生產服務平台。因此，預計主要參與者的這些策略舉措將在預測期內為亞太細胞和基因療法市場創造巨大的成長機會。

亞太細胞和基因治療市場概覽

中國在基因和細胞治療領域正在取得進展。中國擁有龐大的患者群體，這對於開發此類療法的公司來說是一個極具吸引力的市場。中國多家公司正在研發針對癌症和遺傳性疾病等疾病的創新療法，並在基因治療研發方面投入了大量資金。中國於2003年成為首個批准基因治療的國家；自此之後，全球細胞和基因治療發展迅速，其治療潛力也大幅提升。中華人民共和國政府已實施多項監管改革，以促進細胞和基因治療的規範發展。根據2021年發表在《自然》雜誌上的一項研究，全球超過50%的細胞治療試驗在中國進行。中國目前有近400項CAR-T試驗正在進行中，主要針對血液學、腫瘤學和實體腫瘤。隨著復星凱特的Yescarta和藥明巨諾的Relma-cel於2021年獲得國家藥品監督管理局（NMPA）的批准，中國的細胞治療正邁入一個新時代。 2023年10月，科濟生物和信達生物分別獲得國家藥品監督管理局（NMPA）批准，獲得針對B細胞成熟抗原的CAR-T療法新藥上市許可。預計這些療法將很快獲得批准並實現商業化。

亞太細胞及基因治療市場收入及預測（2031年）（百萬美元）

亞太細胞和基因治療市場細分

亞太細胞和基因治療市場按類型、服務、規模、最終用戶和國家分類。

根據類型，亞太細胞和基因治療市場分為細胞治療和基因治療。 2023年，細胞治療佔據了更大的市場。此外，細胞治療細分市場又細分為同種異體載體、自體載體和病毒載體。基因治療細分市場又細分為非病毒載體和病毒載體。

就服務而言，亞太細胞和基因治療市場分為製程開發、cGMP製造、監管服務和生物測定服務。製程開發領域在2023年佔據了最大的市場。

按規模分類，亞太地區細胞和基因治療市場分為商業化前/研發生產和商業化規模生產。 2023年，商業化前/研發生產領域佔據了更大的市場佔有率。

根據最終用戶，亞太細胞和基因治療市場細分為合約研究組織、製藥和生物製藥公司以及學術和研究機構。製藥和生物製藥公司在2023年佔據了最大的市場。

按國家/地區分類，亞太細胞和基因治療市場分為中國、日本、印度、澳洲、韓國和亞太其他地區。 2023年，中國佔據了亞太細胞和基因治療市場的主導地位。

Catalent Inc、Charles River Laboratories International Inc、F. Hoffmann-La Roche Ltd、FUJIFILM Holdings Corp、Lonza Group AG、樂天公司、默克集團、Takara Bio Inc、賽默飛世爾科技公司和藥明康德股份有限公司是亞太細胞和基因治療市場的一些領先公司。

目錄

第1章：簡介

第2章：執行摘要

  • 關鍵見解

第3章：研究方法

  • 二次研究
  • 初步研究
    • 假設表述：
    • 宏觀經濟因素分析：
    • 顯影基數：
    • 數據三角測量：
    • 國家級資料：

第4章：亞太地區細胞與基因治療市場格局

  • 概述
  • PEST分析

第5章：亞太細胞與基因治療市場－關鍵市場動態

  • 細胞與基因治療市場—關鍵市場動態
  • 市場促進因素
    • 細胞和基因療法獲批數量的增加
    • 外包細胞與基因治療製造迅速普及
  • 市場限制
    • 細胞和基因治療製造成本高昂
  • 市場機會
    • 企業的策略舉措
  • 未來趨勢
    • 細胞和基因治療製造服務的自動化
  • 促進因素和限制因素的影響：

第6章：細胞與基因治療市場-亞太市場分析

  • 亞太細胞和基因治療市場概覽
  • 2021-2031年亞太細胞及基因治療市場收入
  • 細胞和基因治療市場預測分析

第7章：亞太地區細胞與基因治療市場分析 - 按類型

  • 細胞療法
  • 基因治療

第8章：亞太地區細胞和基因治療市場分析 - 按服務

  • 製程開發
  • cGMP 製造
  • 監管服務
  • 生物測定服務

第9章：亞太地區細胞與基因治療市場分析－依規模

  • 商業化前/研發製造
  • 商業規模生產

第10章：亞太地區細胞與基因治療市場分析—服務提供者

  • 合約製造與生產組織
  • 首席行銷長

第 11 章：亞太細胞和基因治療市場分析 - 按最終用戶

  • 合約研究組織
  • 製藥和生物製藥公司
  • 學術和研究機構

第 12 章：亞太細胞與基因治療市場 - 國家分析

  • 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
  • 亞太其他地區

第13章：產業格局

  • 概述
  • 細胞和基因治療市場的成長策略
  • 有機成長策略
    • 概述
  • 無機成長策略
    • 概述

第 14 章：公司簡介

  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Charles River Laboratories International Inc
  • Lonza Group AG
  • WuXi AppTec Co Ltd
  • Takara Bio Inc
  • FUJIFILM Holdings Corp
  • F. Hoffmann-La Roche Ltd
  • Catalent Inc
  • Lotte Corp

第 15 章：附錄

Product Code: BMIRE00031472

The Asia Pacific cell and gene therapy market was valued at US$ 1,024.37 million in 2023 and is projected to reach US$ 8,012.75 million by 2031; it is estimated to record a CAGR of 29.3% from 2023 to 2031.

Strategic Initiatives by Companies Drive Asia Pacific Cell and Gene Therapy Market

Many companies involved in manufacturing cell and gene therapy products focus on collaborations, expansions, agreements, partnerships, new product launches, and other strategic developments. These strategic initiatives help them improve sales, expand geographic reach, and enhance capacities to cater to a large customer base. A few of the significant developments in the cell and gene therapy market are; In September 2023, Agilent Technologies Inc. signed a Memorandum of Understanding (MOU) with the Advanced Cell Therapy and Research Institute, Singapore (ACTRIS). This agreement aims to improve cell and gene therapy advancements over the next three years. In March 2023, Cellevolve Bio partnered with Seattle Children's Therapeutics to develop and commercialize new multiplex CARs for pediatric cancers. With this collaboration, the companies will focus on the BrainChild research program-a suite of five multiplex CARs-to treat pediatric central nervous system (CNS) malignancies. They aim to leverage the Seattle Children's Cure Factory facility to conduct early clinical GMP research on new CARs. In March 2023, Twist Bioscience Corporation and Kriya Therapeutics, Inc. entered an antibody discovery agreement for antibodies delivered using adeno-associated viral (AAV) gene therapy in therapeutic oncology applications. Also, the companies aim to combine Twist's antibody libraries with Kriya's proprietary vector engineering platform to discover novel antibodies against specific targets of interest to be delivered with Kriya's gene therapy technology. In January 2023, FUJIFILM Corporation agreed to acquire a cell therapy manufacturing facility from Atara Biotherapeutics, Inc. The facility will witness expansion with the flexibility to produce clinical as well as commercial cell therapies, such as allogeneic T-cell and CAR T immunotherapies. The initiation of new businesses to remain competitive in the market through collaborations and partnerships can help accelerate the development of new platforms for cell and gene therapy manufacturing services. Thus, these strategic initiatives by key players are anticipated to create substantial growth opportunities in the Asia Pacific cell and gene therapy market during the forecast period.

Asia Pacific Cell and Gene Therapy Market Overview

China is making progress in gene and cell therapy. The country has a large patient population making it an attractive market for companies developing these treatments. Several companies are working on innovative therapies for diseases such as cancer and genetic disorders in China, and the country has invested heavily in gene therapy research and development. China was the first country to approve gene therapy in 2003; since then, cell and gene therapy developments have advanced rapidly worldwide, and their therapeutic potential has soared. The government of the People's Republic of China has conducted several regulatory reforms to promote the normative development of cell and gene therapies. According to a study published in Nature in 2021, China is home to more than 50% of all cell therapy trials worldwide. China has nearly 400 ongoing CAR-T trials centered on hematology, oncology, and solid tumors. Cell therapy in China is entering a new era with the approval of Fosun Kite's Yescarta and JW Therapeutics' Relma-cel in 2021 from the National Medical Products Administration (NMPA). In October 2023, CARsgen and IASO Biotherapeutics/Innovent were approved by the NMPA for new drug approvals targeting B-cell maturation antigens in CAR-T. These therapies are expected to be approved and commercialized soon.

Asia Pacific Cell and Gene Therapy Market Revenue and Forecast to 2031 (US$ Million)

Asia Pacific Cell and Gene Therapy Market Segmentation

The Asia Pacific cell and gene therapy market is categorized into type, services, scale, end user, and country.

Based on type, the Asia Pacific cell and gene therapy market is bifurcated into cell therapy and gene therapy. The cell therapy segment held a larger market share in 2023. Furthermore, the cell therapy segment is sub segmented into allogeneic, autologous, viral vectors. Additionally, the gene therapy segment is divided into non-viral vectors and viral vectors.

In terms of services, the Asia Pacific cell and gene therapy market is categorized process development, cGMP manufacturing, regulatory services, and bioassay services. The process development segment held the largest market share in 2023.

By scale, the Asia Pacific cell and gene therapy market is bifurcated into pre-commercial/R&D manufacturing and commercial scale manufacturing. The pre-commercial/R&D manufacturing segment held a larger market share in 2023.

Based on end user, the Asia Pacific cell and gene therapy market is segmented into contract research organizations, pharmaceutical and biopharmaceutical companies, and academic and research institutes. The pharmaceutical and biopharmaceutical companies segment held the largest market share in 2023.

By country, the Asia Pacific cell and gene therapy market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific cell and gene therapy market share in 2023.

Catalent Inc, Charles River Laboratories International Inc, F. Hoffmann-La Roche Ltd, FUJIFILM Holdings Corp, Lonza Group AG, Lotte Corp, Merck KGaA, Takara Bio Inc, Thermo Fisher Scientific Inc., and WuXi AppTec Co Ltd are some of the leading companies operating in the Asia Pacific cell and gene therapy market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macro-economic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country level data:

4. Asia Pacific Cell and Gene Therapy Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis

5. Asia Pacific Cell and Gene Therapy Market - Key Market Dynamics

  • 5.1 Cell and Gene Therapy Market - Key Market Dynamics
  • 5.2 Market Drivers
    • 5.2.1 Increase in Number of Approval of Cell and Gene Therapies
    • 5.2.2 Rapid Popularity of Outsourcing Cell and Gene Therapy Manufacturing
  • 5.3 Market Restraints
    • 5.3.1 High Cost of Cell and Gene Therapy Manufacturing
  • 5.4 Market Opportunities
    • 5.4.1 Strategic Initiatives by Companies
  • 5.5 Future Trends
    • 5.5.1 Automation of Cell and Gene Therapy Manufacturing Services
  • 5.6 Impact of Drivers and Restraints:

6. Cell and Gene Therapy Market -Asia Pacific Market Analysis

  • 6.1 Asia Pacific Cell and Gene Therapy Market Overview
  • 6.2 Asia Pacific Cell and Gene Therapy Market Revenue (US$ Million), 2021-2031
  • 6.3 Cell and Gene Therapy Market Forecast Analysis

7. Asia Pacific Cell and Gene Therapy Market Analysis - by Type

  • 7.1 Cell Therapy
    • 7.1.1 Overview
    • 7.1.2 Cell Therapy: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.2 Gene Therapy
    • 7.2.1 Overview
    • 7.2.2 Gene Therapy: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)

8. Asia Pacific Cell and Gene Therapy Market Analysis - by Services

  • 8.1 Process Development
    • 8.1.1 Overview
    • 8.1.2 Process Development: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.2 cGMP Manufacturing
    • 8.2.1 Overview
    • 8.2.2 cGMP Manufacturing: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.3 Regulatory Services
    • 8.3.1 Overview
    • 8.3.2 Regulatory Services: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.4 Bioassay Services
    • 8.4.1 Overview
    • 8.4.2 Bioassay Services: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)

9. Asia Pacific Cell and Gene Therapy Market Analysis - by Scale

  • 9.1 Pre-Commercial/R&D Manufacturing
    • 9.1.1 Overview
    • 9.1.2 Pre-Commercial/R&D Manufacturing: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.2 Commercial Scale Manufacturing
    • 9.2.1 Overview
    • 9.2.2 Commercial Scale Manufacturing: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)

10. Asia Pacific Cell and Gene Therapy Market Analysis - by Service Providers

  • 10.1 CDMOs
    • 10.1.1 Overview
    • 10.1.2 CDMOs: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.2 CMOs
    • 10.2.1 Overview
    • 10.2.2 CMOs: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)

11. Asia Pacific Cell and Gene Therapy Market Analysis - by End User

  • 11.1 Contract Research Organizations
    • 11.1.1 Overview
    • 11.1.2 Contract Research Organizations: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • 11.2 Pharmaceutical and Biopharmaceutical Companies
    • 11.2.1 Overview
    • 11.2.2 Pharmaceutical and Biopharmaceutical Companies: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • 11.3 Academic and Research Institutes
    • 11.3.1 Overview
    • 11.3.2 Academic and Research Institutes: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)

12. Asia Pacific Cell and Gene Therapy Market - Country Analysis

  • 12.1 Asia Pacific Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
    • 12.1.1 Asia Pacific Cell and Gene Therapy Market - Revenue and Forecast Analysis - by Country
      • 12.1.1.1 Asia Pacific: Cell and Gene Therapy Market - Revenue and Forecast Analysis - by Country
      • 12.1.1.2 China: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
        • 12.1.1.2.1 China: Cell and Gene Therapy Market Breakdown, by Type
          • 12.1.1.2.1.1 China: Cell and Gene Therapy Market Breakdown, by Cell Therapy
          • 12.1.1.2.1.2 China: Cell and Gene Therapy Market Breakdown, by Gene Therapy
        • 12.1.1.2.2 China: Cell and Gene Therapy Market Breakdown, by Services
        • 12.1.1.2.3 China: Cell and Gene Therapy Market Breakdown, by Scale
        • 12.1.1.2.4 China: Cell and Gene Therapy Market Breakdown, by Service Providers
        • 12.1.1.2.5 China: Cell and Gene Therapy Market Breakdown, by End User
      • 12.1.1.3 Japan: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
        • 12.1.1.3.1 Japan: Cell and Gene Therapy Market Breakdown, by Type
          • 12.1.1.3.1.1 Japan: Cell and Gene Therapy Market Breakdown, by Cell Therapy
          • 12.1.1.3.1.2 Japan: Cell and Gene Therapy Market Breakdown, by Gene Therapy
        • 12.1.1.3.2 Japan: Cell and Gene Therapy Market Breakdown, by Services
        • 12.1.1.3.3 Japan: Cell and Gene Therapy Market Breakdown, by Scale
        • 12.1.1.3.4 Japan: Cell and Gene Therapy Market Breakdown, by Service Providers
        • 12.1.1.3.5 Japan: Cell and Gene Therapy Market Breakdown, by End User
      • 12.1.1.4 India: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
        • 12.1.1.4.1 India: Cell and Gene Therapy Market Breakdown, by Type
          • 12.1.1.4.1.1 India: Cell and Gene Therapy Market Breakdown, by Cell Therapy
          • 12.1.1.4.1.2 India: Cell and Gene Therapy Market Breakdown, by Gene Therapy
        • 12.1.1.4.2 India: Cell and Gene Therapy Market Breakdown, by Services
        • 12.1.1.4.3 India: Cell and Gene Therapy Market Breakdown, by Scale
        • 12.1.1.4.4 India: Cell and Gene Therapy Market Breakdown, by Service Providers
        • 12.1.1.4.5 India: Cell and Gene Therapy Market Breakdown, by End User
      • 12.1.1.5 Australia: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
        • 12.1.1.5.1 Australia: Cell and Gene Therapy Market Breakdown, by Type
          • 12.1.1.5.1.1 Australia: Cell and Gene Therapy Market Breakdown, by Cell Therapy
          • 12.1.1.5.1.2 Australia: Cell and Gene Therapy Market Breakdown, by Gene Therapy
        • 12.1.1.5.2 Australia: Cell and Gene Therapy Market Breakdown, by Services
        • 12.1.1.5.3 Australia: Cell and Gene Therapy Market Breakdown, by Scale
        • 12.1.1.5.4 Australia: Cell and Gene Therapy Market Breakdown, by Service Providers
        • 12.1.1.5.5 Australia: Cell and Gene Therapy Market Breakdown, by End User
      • 12.1.1.6 South Korea: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
        • 12.1.1.6.1 South Korea: Cell and Gene Therapy Market Breakdown, by Type
          • 12.1.1.6.1.1 South Korea: Cell and Gene Therapy Market Breakdown, by Cell Therapy
          • 12.1.1.6.1.2 South Korea: Cell and Gene Therapy Market Breakdown, by Gene Therapy
        • 12.1.1.6.2 South Korea: Cell and Gene Therapy Market Breakdown, by Services
        • 12.1.1.6.3 South Korea: Cell and Gene Therapy Market Breakdown, by Scale
        • 12.1.1.6.4 South Korea: Cell and Gene Therapy Market Breakdown, by Service Providers
        • 12.1.1.6.5 South Korea: Cell and Gene Therapy Market Breakdown, by End User
      • 12.1.1.7 Rest of Asia Pacific: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
        • 12.1.1.7.1 Rest of Asia Pacific: Cell and Gene Therapy Market Breakdown, by Type
          • 12.1.1.7.1.1 Rest of Asia Pacific: Cell and Gene Therapy Market Breakdown, by Cell Therapy
          • 12.1.1.7.1.2 Rest of Asia Pacific: Cell and Gene Therapy Market Breakdown, by Gene Therapy
        • 12.1.1.7.2 Rest of Asia Pacific: Cell and Gene Therapy Market Breakdown, by Services
        • 12.1.1.7.3 Rest of Asia Pacific: Cell and Gene Therapy Market Breakdown, by Scale
        • 12.1.1.7.4 Rest of Asia Pacific: Cell and Gene Therapy Market Breakdown, by Service Providers
        • 12.1.1.7.5 Rest of Asia Pacific: Cell and Gene Therapy Market Breakdown, by End User

13. Industry Landscape

  • 13.1 Overview
  • 13.2 Growth Strategies in Cell and Gene Therapy Market
  • 13.3 Organic Growth Strategies
    • 13.3.1 Overview
  • 13.4 Inorganic Growth Strategies
    • 13.4.1 Overview

14. Company Profiles

  • 14.1 Thermo Fisher Scientific Inc.
    • 14.1.1 Key Facts
    • 14.1.2 Business Description
    • 14.1.3 Products and Services
    • 14.1.4 Financial Overview
    • 14.1.5 SWOT Analysis
    • 14.1.6 Key Developments
  • 14.2 Merck KGaA
    • 14.2.1 Key Facts
    • 14.2.2 Business Description
    • 14.2.3 Products and Services
    • 14.2.4 Financial Overview
    • 14.2.5 SWOT Analysis
    • 14.2.6 Key Developments
  • 14.3 Charles River Laboratories International Inc
    • 14.3.1 Key Facts
    • 14.3.2 Business Description
    • 14.3.3 Products and Services
    • 14.3.4 Financial Overview
    • 14.3.5 SWOT Analysis
    • 14.3.6 Key Developments
  • 14.4 Lonza Group AG
    • 14.4.1 Key Facts
    • 14.4.2 Business Description
    • 14.4.3 Products and Services
    • 14.4.4 Financial Overview
    • 14.4.5 SWOT Analysis
    • 14.4.6 Key Developments
  • 14.5 WuXi AppTec Co Ltd
    • 14.5.1 Key Facts
    • 14.5.2 Business Description
    • 14.5.3 Products and Services
    • 14.5.4 Financial Overview
    • 14.5.5 SWOT Analysis
    • 14.5.6 Key Developments
  • 14.6 Takara Bio Inc
    • 14.6.1 Key Facts
    • 14.6.2 Business Description
    • 14.6.3 Products and Services
    • 14.6.4 Financial Overview
    • 14.6.5 SWOT Analysis
    • 14.6.6 Key Developments
  • 14.7 FUJIFILM Holdings Corp
    • 14.7.1 Key Facts
    • 14.7.2 Business Description
    • 14.7.3 Products and Services
    • 14.7.4 Financial Overview
    • 14.7.5 SWOT Analysis
    • 14.7.6 Key Developments
  • 14.8 F. Hoffmann-La Roche Ltd
    • 14.8.1 Key Facts
    • 14.8.2 Business Description
    • 14.8.3 Products and Services
    • 14.8.4 Financial Overview
    • 14.8.5 SWOT Analysis
    • 14.8.6 Key Developments
  • 14.9 Catalent Inc
    • 14.9.1 Key Facts
    • 14.9.2 Business Description
    • 14.9.3 Products and Services
    • 14.9.4 Financial Overview
    • 14.9.5 SWOT Analysis
    • 14.9.6 Key Developments
  • 14.10 Lotte Corp
    • 14.10.1 Key Facts
    • 14.10.2 Business Description
    • 14.10.3 Products and Services
    • 14.10.4 Financial Overview
    • 14.10.5 SWOT Analysis
    • 14.10.6 Key Developments

15. Appendix

  • 15.1 About The Insight Partners
  • 15.2 Glossary of Terms

List Of Tables

  • Table 1. Cell and Gene Therapy Market Segmentation
  • Table 2. Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • Table 3. Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million) - by Type
  • Table 4. Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million) - by Cell Therapy
  • Table 5. Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million) - by Gene Therapy
  • Table 6. Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million) - by Services
  • Table 7. Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million) - by Scale
  • Table 8. Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million) - by Service Providers
  • Table 9. Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million) - by End User
  • Table 10. Asia Pacific: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Country
  • Table 11. China: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 12. China: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Cell Therapy
  • Table 13. China: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Gene Therapy
  • Table 14. China: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Services
  • Table 15. China: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Scale
  • Table 16. China: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Service Providers
  • Table 17. China: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 18. Japan: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 19. Japan: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Cell Therapy
  • Table 20. Japan: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Gene Therapy
  • Table 21. Japan: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Services
  • Table 22. Japan: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Scale
  • Table 23. Japan: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Service Providers
  • Table 24. Japan: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 25. India: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 26. India: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Cell Therapy
  • Table 27. India: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Gene Therapy
  • Table 28. India: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Services
  • Table 29. India: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Scale
  • Table 30. India: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Service Providers
  • Table 31. India: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 32. Australia: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 33. Australia: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Cell Therapy
  • Table 34. Australia: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Gene Therapy
  • Table 35. Australia: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Services
  • Table 36. Australia: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Scale
  • Table 37. Australia: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Service Providers
  • Table 38. Australia: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 39. South Korea: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 40. South Korea: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Cell Therapy
  • Table 41. South Korea: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Gene Therapy
  • Table 42. South Korea: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Services
  • Table 43. South Korea: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Scale
  • Table 44. South Korea: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Service Providers
  • Table 45. South Korea: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 46. Rest of Asia Pacific: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 47. Rest of Asia Pacific: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Cell Therapy
  • Table 48. Rest of Asia Pacific: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Gene Therapy
  • Table 49. Rest of Asia Pacific: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Services
  • Table 50. Rest of Asia Pacific: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Scale
  • Table 51. Rest of Asia Pacific: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Service Providers
  • Table 52. Rest of Asia Pacific: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 53. Recent Organic Growth Strategies in Cell and Gene Therapy Market
  • Table 54. Recent Inorganic Growth Strategies in the Cell and Gene Therapy Market
  • Table 55. Glossary of Terms

List Of Figures

  • Figure 1. Cell and Gene Therapy Market Segmentation, by Country
  • Figure 2. PEST Analysis
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Cell and Gene Therapy Market Revenue (US$ Million), 2021-2031
  • Figure 5. Cell and Gene Therapy Market Share (%) - by Type (2023 and 2031)
  • Figure 6. Cell Therapy: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 7. Gene Therapy: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 8. Cell and Gene Therapy Market Share (%) - by Services (2023 and 2031)
  • Figure 9. Process Development: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 10. cGMP Manufacturing: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 11. Regulatory Services: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 12. Bioassay Services: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 13. Cell and Gene Therapy Market Share (%) - by Scale (2023 and 2031)
  • Figure 14. Pre-Commercial/R&D Manufacturing: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 15. Commercial Scale Manufacturing: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 16. Cell and Gene Therapy Market Share (%) - by Service Providers (2023 and 2031)
  • Figure 17. CDMOs: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 18. CMOs: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 19. Cell and Gene Therapy Market Share (%) - by End User (2023 and 2031)
  • Figure 20. Contract Research Organizations: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 21. Pharmaceutical and Biopharmaceutical Companies: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 22. Academic and Research Institutes: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 23. Asia Pacific Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 24. Asia Pacific Cell and Gene Therapy Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 25. China: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 26. Japan: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 27. India: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 28. Australia: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 29. South Korea: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 30. Rest of Asia Pacific: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 31. Growth Strategies in Cell and Gene Therapy Market